Cargando…

Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland

OBJECTIVES: Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international comm...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Erin A., Anker, Daniela, Amati, Rebecca, Richard, Aude, Wisniak, Ania, Butty, Audrey, Albanese, Emiliano, Bochud, Murielle, Chiolero, Arnaud, Crivelli, Luca, Cullati, Stéphane, d’Acremont, Valérie, Epure, Adina Mihaela, Fehr, Jan, Flahault, Antoine, Fornerod, Luc, Frank, Irène, Frei, Anja, Michel, Gisela, Gonseth, Semira, Guessous, Idris, Imboden, Medea, Kahlert, Christian R., Kaufmann, Laurent, Kohler, Philipp, Mösli, Nicolai, Paris, Daniel, Probst-Hensch, Nicole, Rodondi, Nicolas, Stringhini, Silvia, Vermes, Thomas, Vollrath, Fabian, Puhan, Milo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584867/
https://www.ncbi.nlm.nih.gov/pubmed/33098441
http://dx.doi.org/10.1007/s00038-020-01494-0
Descripción
Sumario:OBJECTIVES: Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international community. METHODS: Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented by Swiss School of Public Health (SSPH+). Over 28,340 participants, randomly selected and age-stratified, with some regional specificities will be included. Additional studies in vulnerable and highly exposed subpopulations are also planned. The studies will assess population immunological status during the pandemic. RESULTS: Phase one (first wave of pandemic) estimates from Geneva showed a steady increase in seroprevalence up to 10.8% (95% CI 8.2–13.9, n = 775) by May 9, 2020. Since June, Zurich, Lausanne, Basel City/Land, Ticino, and Fribourg recruited a total of 5973 participants for phase two thus far. CONCLUSIONS: Corona Immunitas will generate reliable, comparable, and high-quality serological and epidemiological data with extensive coverage of Switzerland and of several subpopulations, informing health policies and decision making in both economic and societal sectors. ISRCTN Registry: https://www.isrctn.com/ISRCTN18181860. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00038-020-01494-0) contains supplementary material, which is available to authorized users.